A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. (Q54604759)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. (English)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Helen J Mackay

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Heather J Au

2

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Elaine McWhirter

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Thierry Alcindor

4

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Andrea Jarvi

5

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Katrina MacAlpine

6

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Lisa Wang

7

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

John J Wright

8

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Amit M Oza

9

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

publication date

12 March 2011

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Investigational New Drugs

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

30

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

1158-1163

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

https://scigraph.springernature.com/pub.10.1007/s10637-011-9650-4

0 references

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Cellular functions regulated by Src family kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Src family kinases in tumor progression and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

pp60c-src protein kinase activity in human gastric carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

pp60c-src activation in gastric carcinoma: a preliminary study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Inhibition of Src impairs the growth of met-addicted gastric tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9650-4

21 January 2018

Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21400081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21400081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21400081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

1 reference

https://pubmed.ncbi.nlm.nih.gov/21400081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression patterns of the novel catenin p120cas in gastrointestinal cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21400081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression patterns of the E-cadherin-catenin cell-cell adhesion complex in gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21400081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9650-4

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21400081

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54604759&oldid=1408681026"